melphalan and Orbital-Neoplasms

Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carboplatin; Child, Preschool; Drug Therapy, Combination; Humans; Infusions, Intra-Arterial; Magnetic Resonance Imaging; Male; Melphalan; Ophthalmic Artery; Orbital Neoplasms; Retinal Neoplasms; Retinoblastoma; Topoisomerase I Inhibitors; Topotecan

The authors describe 4 cases of multiple myeloma that developed one or more extraskeletal localizations. They have evaluated the relation between the onset of the extraskeletal localizations and the following myeloma characteristics: tumor burden, clinical phase, chemotherapy response, prognostic significance. All the patients showed these localizations in a plateau phase of myeloma. None of the patients had fever, pancytopenia and in no one the performance status worsened. All patients obtained at least a partial reduction of the localization and only the patient with the retro-orbital localization, got worse and died for myeloma. The other three patients are alive and do not show any sign of progression.

Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Laryngeal Neoplasms; Male; Melphalan; Middle Aged; Multiple Myeloma; Orbital Neoplasms; Prednisone; Prognosis; Stomach Neoplasms; Testicular Neoplasms; Vincristine

An 81-year-old man presented with bilateral orbital tumors that were found to be extramedullary plasmacytomas. Immunoperoxidase staining of the tissue was positive for IgG-kappa; no lambda chains were seen. Results of serum immunoelectrophoresis were positive for monoclonal IgG-kappa. Test results of the urine were positive for Bence Jones protein; only kappa chains were seen on radial diffusion. Systemic evaluation failed to show tumor elsewhere. The patient was treated with radiation and low-dose melphalan/prednisone, with good response. Five years later, the results of immunoelectrophoresis are normal and there is no clinical evidence of tumor; however, a small amount of kappa light chains remains in the urine. This case supports the important therapeutic and prognostic differences among orbital involvement in extramedullary plasmacytoma, solitary myeloma of bone, and multiple myeloma.

Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Humans; Male; Melphalan; Orbital Neoplasms; Plasmacytoma; Prednisone; Tomography, X-Ray Computed

Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Orbital Neoplasms; Prednisone; Tomography, X-Ray Computed; Vincristine

Topics: Adult; Bone Neoplasms; Exophthalmos; Female; Humans; Melphalan; Multiple Myeloma; Orbital Neoplasms; Sphenoid Bone

Topics: Female; Humans; Melphalan; Middle Aged; Multiple Myeloma; Orbital Neoplasms

Topics: Adolescent; Child; Geriatrics; Head and Neck Neoplasms; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Mandibular Neoplasms; Maxillary Neoplasms; Melanoma; Melphalan; Multiple Myeloma; Neoplasms; Orbital Neoplasms; Plasmacytoma; Sarcoma; Sarcoma, Kaposi